About Index Trending news
Analyze
Top 50 Pricing
Resverlogix Corp.

Resverlogix Corp.

Work at Resverlogix Corp.? Add yourself to this profile

Resverlogix Corp.

RVX-208 is a first-in-class, selective BET bromodomain inhibitor treating patients with cardiovascular disease, diabetes mellitus, and other serious diseases.

Elsewhere

Alexa global traffic share

Twitter followers

03 Jul 2014
$30,000,000
Post-IPO debt
11 Jun 2014
$2,300,000
Post-IPO equity
29 Mar 2010
$25,000,000
Venture capital